Measuring MS

Neurologist Peter Chin discusses the evolution of measuring multiple sclerosis.

Over the past decade I’ve worked in clinical development to advance new medicines to treat multiple sclerosis (MS). My job has been to design clinical trials and monitor the data they generate to determine a potential medicine’s safety and efficacy. One question we aim to answer is whether the new medicine is more effective than what’s already available. Answering this question of efficacy requires tools for measuring and comparing both the state and progression of the disease.

It’s complicated

Measuring the impact of MS isn’t as simple as unspooling a tape measure – we’re limited both by what a patient can report and what a neurologist can assess. The biology of MS is not fully understood, symptoms of MS vary from person to person, and the biological markers of MS don’t always correlate with a patient’s clinical signs and symptoms. MS usually appears early in life and it is a chronic, lifelong disease, where symptoms typically evolve over time. Furthermore, there are different subtypes of MS.

Most people living with MS have the relapsing form, in which new symptoms abruptly appear or old symptoms worsen for a limited period of time and are followed by either full or partial recovery, in episodes known as relapses or MS attacks. Others have progressive MS, in which the disease steadily worsens over time. Thus, demonstrating the efficacy of treatments for MS is complicated and the science around this continuously evolves.

In designing a therapeutic clinical trial, patients are randomly assigned into two or more treatment groups, those receiving the new medicine and those receiving an existing treatment or placebo (also known as the control group). Then we identify patient outcomes that are important in that disease and use them to define the trial’s endpoints, which are quantified outcome measures used to formally compare results between the two groups. We assess all of the patients over time, record their outcomes during the trial, and compare the two groups at the end of the trial using the pre-defined endpoints.

At present, neurologists use three major types of outcome measures to assess the state of one’s MS disease: frequency of relapses; physical disability status; and biological markers, including brain scans using MRI. In MS clinical trials, these same types of outcomes are used to define the specific endpoints to be statistically analysed.

Relapses

measuring-multiple-sclerosis-glossarymeasuring-multiple-sclerosis-glossary are meaningful as they reflect how individuals experience fluctuations in symptoms that are central to relapsing MS. In many clinical trials, the relapse frequency, measured by the, is a primary endpoint. For progressive MS, where relapses don’t occur frequently, other endpoints are used.

Physical disability

is an important measure to track because MS is a chronic condition where a person’s functional disability worsens over time. A neurologist’s physical examination is still the gold standard for its measurement. That examination is a remarkable process and reflects the foundation of what a neurologist does. We use our eyes, ears and hands to assess a patient’s problems with cognition, vision, strength, coordination, sensation, walking and agility. In order to compare one patient to another (or one patient to himself or herself over time), we’ve developed ways to rate the individual symptom assessments numerically and then combine them into a single score. The most widely used neurologic exam in MS is called the, which is often used as an endpoint in clinical trials. The goal is to find medicines that stabilise or potentially even improve disability scores.

Biological markers

In the early 1980s, a new assessment tool became available –brain scans. For the first time, we could actually see lesions or damaged areas in the brain, and we could count new lesions by comparing MRI scans over time. When drug approval agencies evaluate new medicines, however, they prefer to rely on clinical outcomes that more closely reflect the patient’s symptomology – relapses and disability scores. Nonetheless, MRI is a valuable secondary tool in both clinical trials and in individual patient care. MRI can highlight the presence of MS disease activity in the brain, whether or not this activity directly results in physical, cognitive or visual symptoms a person may experience.

Composite measures

There’s no single measure that captures the entire MS experience. As more becomes known about the biology of disease and treatment, the field develops newer ways to integrate relapse records, disability scores and biological markers. One example of progress in MS outcomes measurement is, an acronym for No Evidence of Disease Activity. If, over a certain period, a patient experiences no relapses, if his or her disability score remains stable and if no new or enlarged brain lesions appear in MRI scans, then that patient can be classified as having achieved NEDA. It provides a simple “yes/no” endpoint for a clinical trial, investigating whether a new medicine increases the percentage of patients with NEDA compared to an existing medicine. Emerging combination endpoints that give us a fuller, more comprehensive picture of the disease in clinical trials may find their way into clinical practice to help doctors make treatment decisions.

Where is MS measurement headed?

Our measurements have improved, but there’s more to be done. There’s a symbiotic relationship between our understanding of MS and our tools for measuring it – better understanding leads to better tools, and better tools lead to better understanding. But it’s perhaps overly optimistic to expect an exact measurement tool, as the disease is very complex.

John Tukey, a mathematician who developed an algorithm that is fundamental to investigating MS with MRI, said it well: “Far better an approximate answer to the right question, which is often vague, than an exact answer to the wrong question, which can always be made precise.”

We learn as we go, both in science and in measurement of outcomes. At Roche, we’re committed to advancing on both fronts.

For more information and a comprehensive list of MS measurements, click.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.